[en] In this article, we will discuss about hypophosphatemia due to tumor-induced osteomalacia. This disease is characterized by severe muscular and articular tenderness inducing profound walking limitation. Clinical chemistry results show severe hypophosphatemia due to hyperphosphaturia. Fibroblast growth factor 23 (FGG-23) is abnormally high. Physiological role of FGF-23 is examined. We also consider the pathophysiology of tumor induced osteomalacia, the use of different investigations to localize the tumor and therapies available to treat this rare disease. [fr] Dans cet article, nous discutons la problématique de l'hypophosphatémie acquise dans le cadre d'une ostéomalacie oncogénique. La maladie se caractérise par une faiblesse musculaire et des douleurs articulaires diffuses entraînant une impotence fonctionnelle majeure. La biologie met en évidence une hypophosphatémie sévère consécutive à une hyperphosphaturie. Le Fibroblast growth factor (FGF-23) est anormalement élevé. Le rôle physiologique du FGF-23 est rappelé. Nous envisageons ensuite la physiopathologie, les diverses investigations ainsi que les différents moyens thérapeutiques à notre disposition pour traiter l'ostéomalacie oncogénique.
Dennis VW. Phosphate metabolism: Contribution of different cellular compartments. Kidney Int 1996;49:938-42. (Pubitemid 26122696)
Prie D, Urena TP, Friedlander G. Latest findings in phosphate homeostasis. Kidney Int 2009;75:882-9.
Delanaye P, Krzesinski JM. Nouveautés à propos du métabolisme du phosphore. Rev Med Liege 2005;60:189-97.
Hesse E, Rosenthal H, Bastian L. Radiofrequency ablation of a tumor causing oncogenic osteomalacia. N Engl J Med 2007;357:422-4. (Pubitemid 47124162)
Seufert J, Ebert K, Muller J, et al. Octreotide therapy for tumor-induced osteomalacia. N Engl J Med 2001;345:1883-8. (Pubitemid 33716563)
Radaideh AR, Jaradat D, Abu-Kalaf MM, et al. Resolution of severe oncogenic hypophosphatemic osteomalacia after resection of a deeply located soft-tissue tumour. Curr Oncol 2009;16:87-90.
Khadgawat R, Singh Y, Kansara S, et al. PET/CT localisation of a scapular haemangiopericytoma with tumour-induced osteomalacia. Singapore Med J 2009;50:e55-7.
Hannan FM, Athanasou NA, Teh J, et al. Oncogenic hypophosphataemic osteomalacia: Biomarker roles of fibroblast growth factor 23, 1,25-dihydroxyvitamin D3 and lymphatic vessel endothelial hyaluronan receptor 1. Eur J Endocrinol 2008;158:265-71.
Shaikh A, Berndt T, Kumar R. Regulation of phosphate homeostasis by the phosphatonins and other novel mediators. Pediatr Nephrol 2008;23:1203-10.
Prie D, Torres PU, Friedlander G. Un nouveau système de régulation du bilan du phosphate: Fibroblast Growth Factor 23-Klotho. Nephrol Ther 2009;5:513-9.
Prie D, Friedlander G. Genetic disorders of renal phosphate transport. N Engl J Med 2010;362:2399-409.
Dupond JL, Mahammedi H, Prie D, et al. Oncogenic osteomalacia: Diagnostic importance of fibroblast growth factor 23 and F-18 fluorodeoxyglucose PET/CT scan for the diagnosis and follow-up in one case. Bone 2005;36:375-8. (Pubitemid 40403835)
Gershinsky M, Croitoru S, Dickstein G, et al. Imaging of oncogenic osteomalacia. Isr Med Assoc J 2007;9:566-7. (Pubitemid 47193391)
Courbebaisse M, Souberbielle JC. Equilibre phosphocalcique: régulation et explorations. Nephrol Ther 2011;7:118-38.
Fukumoto S. Physiological regulation and disorders of phosphate metabolism - pivotal role of fibroblast growth factor 23. Intern Med 2008;47:337-43. (Pubitemid 351663682)
*Jonsson KB, Zahradnik R, Larsson T, et al. Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia. N Engl J Med 2003;348:1656-63. (Pubitemid 36459471)
Geller JL, Khosravi A, Kelly MH, et al. Cinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res 2007;22:931-7.
Kronenberg HM. NPT2a - the key to phosphate homeostasis. N Engl J Med 2002;347:1022-4.
Takeuchi Y, Suzuki H, Ogura S, et al. Venous sampling for fibroblast growth factor-23 confirms preoperative diagnosis of tumor-induced osteomalacia. J Clin Endocrinol Metab 2004;89:3979-82. (Pubitemid 39071502)
Kimizuka T, Ozaki Y, Sumi Y. Usefulness of 201Tl and 99mTc MIBI scintigraphy in a case of oncogenic osteomalacia. Ann Nucl Med 2004;18:63-7. (Pubitemid 38478411)
Jan de Beur SM, Streeten EA, Civelek AC, et al. Localisation of mesenchymal tumours by somatostatin receptor imaging. Lancet 2002;359:761-3. (Pubitemid 34215078)
Al Nahhas A, Win Z, Szyszko T, et al. Gallium-68 PET: A new frontier in receptor cancer imaging. Anticancer Res 2007;27:4087-94.
Hesse E, Moessinger E, Rosenthal H, et al. Oncogenic osteomalacia: Exact tumor localization by co-registration of positron emission and computed tomography. J Bone Miner Res 2007;22:158-62. (Pubitemid 46032609)
Dowman JK, Khattak FH. Oncogenic hypophosphataemic osteomalacia mimicking bone metastases on isotope bone scan. Ann Rheum Dis 2006;65:1664. (Pubitemid 44799685)
Cavalier E, Delanaye P, Chapelle JP, et al. Vitamin D: Current status and perspectives. Clin Chem Lab Med 2009;47:120-7.
Holick MF. The vitamin D deficiency pandemic and consequences for nonskeletal health: Mechanisms of action. Mol Aspects Med 2008;29:361-8.
Michaut P, Prie D, Amiel C, et al. Dipyridamole for renal phosphate leak ? N Engl J Med 1994;331:58-9.